NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









HotSpot Therapeutics

HotSpot Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.hotspotthera.com/

Last Round

Series C

Nov 29, 2021

Total Funding Raised

$210M

Company Overview

HotSpot Therapeutics is a biotechnology company that pioneers allosteric drug discovery by identifying and targeting natural regulatory hotspots on proteins to develop differentiated small molecule medicines for autoimmune diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

small moleculedrug discoveryallosteric inhibitorsbiotechprecision medicineoncologyautoimmune diseaseundruggable targetsAI drug discoverypreclinical researchcomputational biologypharma partneringin silico drug designtechbio

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HotSpot Therapeutics Comps

Public and private peers based on sector, stage, and business model.

HotSpot Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

HotSpot Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 29, 2021
Series BMay 21, 2020
Series AJul 17, 2018

Key People

Founding team and executive leadership

Jonathan Montagu

President Chief Executive Officer

Executive Team

Eva Jack

Chief Operating Officer

Executive Team

HotSpot Therapeutics Investors

Notable investors and investment history

HotSpot Therapeutics investors
InvestorRounds
Brace Pharma CapitalSeries B
EQT Life SciencesSeries C
B Capital GroupSeries C
Pivotal bioVenture PartnersSeries C
Tekla Capital ManagementSeries B, Series C
Nan Fung GroupSeries C
Solasta VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    Presented preclinical data at the 15th European Lupus Meeting.

  • Mar 4, 2026

    Launched interferon regulatory factor 5 (IRF5) program with preclinical data.

HotSpot Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HotSpot Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HotSpot Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range59
Year Founded2017
Last FundingNov 29, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.